We focus on indications and target proteins where our technology platform offers us a competitive advantage and where there is a high unmet medical need in well-defined patient populations.
ABY-271
ABY-271 is a radiotherapeutic candidate designed to target tumor cells expressing HER2, a well-validated receptor overexpressed in several cancers, including breast and gastric cancers. The Affibody® targeting moiety binds to domain III of HER2 (distinct from existing HER2-targeted therapies, enabling combination approaches) and is conjugated to 177Lu, a clinically and commercially validated β-emitter.
HER2 targeting has been confirmed in hundreds of patients using PET analog tezatabep matrazetan. Preclinical studies demonstrate strong and sustained tumor uptake at all timepoints. In xenograft models, a single dose of ABY-271 shows therapeutic efficacy as monotherapy and achieves survival and complete remission when combined with trastuzumab.
A first-in-human clinical study in patients with HER2-positive metastatic breast cancer is currently underway, with first results expected in 2025.
Tezatabep matraxetan
Tezatabep matraxetan (ABY-025) is a Gallium-68-labeled PET tracer candidate that aims to enable non-invasive and cost-effective PET imaging diagnosis of HER2 expression in cancer patients.
Affibody is collaborating with internationally acknowledged academic institutions to explore the clinical utility of tezatabep matraxetan, which is currently being evaluated globally in investigator-initiated studies. Phase 2 results with tezatabep matraxetan indicate that the compound can be used both to detect HER2 expression and monitor therapy response.
In recent years, the interest has increased in treating patients with low HER2 expression and Affibody has successfully shown that it is possible to identify patients with low HER2 expression with ABY-025. Results from a clinical trial demonstrating this have been published in the Journal of Nuclear Medicine (JNM) in May 2024.
